Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

Volker Heinemann,L. Fischer von Weikersthal,Ursula Vehling-Kaiser,Martina Stauch,Daniel Oruzio,M. Schulze,Holger Hass,J. Weiss,H. Dietzfelbinger,Nicolas Moosmann

Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group

2008

Volker Heinemann
L. Fischer von Weikersthal
Ursula Vehling-Kaiser
Martina Stauch
Daniel Oruzio
M. Schulze
Holger Hass
J. Weiss
H. Dietzfelbinger
Nicolas Moosmann

4033 Background: Cetuximab combined with 5-fluorouracil/folinic acid (5-FU/FA) plus irinotecan or oxaliplatin has shown activity in the treatment of mCRC. This randomized trial compared the first-l...

Keywords:

XELIRI
Cetuximab
Randomized controlled trial
Colorectal cancer
Oncology
German
Medicine
Internal medicine
Irinotecan
Folinic acid
Oxaliplatin
first line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations